In addition to Indi and Caprion, the STM paper, which is titled "A
Blood-Based Proteomic Classifier for the Molecular Characterization of
Pulmonary Nodules", also included the participation and/or the
provision of clinical specimens from investigators and collaborators at
Institute for Systems Biology (ISB), the British Columbia Cancer
Agency, ISB, the Institut Universitaire de Cardiologie et de
Pneumologie de Quebec, the New York University Langone Medical Center
and School of Medicine, the Perelman School of Medicine at the
University of Pennsylvania, and the Vanderbilt University Medical
About Caprion Proteomics
Caprion is the leading provider of proteomics biomarker and immune
monitoring services to the pharmaceutical and biotechnology industry.
Its proprietary proteomics technology, CellCarta®, is a gel-free, label-free mass spectrometry (MS) platform that enables
a comprehensive, quantitative and robust comparative measurement of
proteins across large sets of biological samples for the discovery and
validation of protein biomarkers. Its proprietary immune monitoring
platform, ImmuneCarta®, offers multiparametric flow cytometry analysis for functional analyses
of innate and adaptive immune responses. Caprion also leverages
CellCarta® to develop its own in-vitro diagnostic products targeting cancer, metabolic and infectious diseases. With research
sites in Montreal, Canada and in Menlo Park, CA, Caprion has been
providing large-scale proteomics and immune monitoring services to over
50 major pharmaceutical and biotech clients for more than 10 years.
Caprion also serves as a biomarker center of excellence for the U.S.
Government/NIH-NIAID for Biodefense research. Caprion acquired PPD
Biomarker Discovery Sciences, LLC from PPD Inc. in 2010, and the assets
of the National Immune Monitoring Laboratory in 2011. Caprion
Proteomics, a privately-held company, is majority owned by Chicago
Growth Partners. For more information, please visit www.caprion.com.
Indi (Integrated Diagnostics) is creating powerful new tools to help
physicians manage complex diseases with a non-invasive blood test. The
company's first test measures multiple blood proteins linked to
pulmonary nodules. The aim of the test is to help physicians identify
patients whose nodules are likely to be benign, eliminating the risks
they face from biopsies and surgeries. www.IndiDx.com
The company, co-founded in October 2009 by systems-biology pioneer Dr.
Lee Hood, is conceptually based on a systems view of disease where
pathophysiology arises from disease-perturbed networks of proteins,
genes, and other molecules. Investors include InterWest Partners and
The Wellcome Trust. Foundational intellectual property is exclusively
licensed from the Institute for Systems Biology and Caltech. Learn more
SOURCE Caprion Proteomics